Top Suppliers:I want be here


78473-71-9

78473-71-9 structure
78473-71-9 structure
  • Name: Enterolactone
  • Chemical Name: enterolactone
  • CAS Number: 78473-71-9
  • Molecular Formula: C18H18O4
  • Molecular Weight: 298.33
  • Catalog: Signaling Pathways Apoptosis Apoptosis
  • Create Date: 2018-10-17 02:19:57
  • Modify Date: 2024-01-04 08:50:25
  • Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity[1]. Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis[2].

Name enterolactone
Synonyms HPMF
HBBL
(3R,4R)-3,4-Bis(3-hydroxybenzyl)dihydrofuran-2(3H)-one
trans-Dihydro-3,4-bis[(3-hydroxyphenyl)methyl]-2(3H)-furanone
Enterolaktone
2(3H)-Furanone, dihydro-3,4-bis((3-hydroxyphenyl)methyl)-, (3R,4R)-rel-
2(3H)-Furanone, dihydro-3,4-bis((3-hydroxyphenyl)methyl)-, trans-
Enterolakton
2(3H)-Furanone, dihydro-3,4-bis[(3-hydroxyphenyl)methyl]-, (3R,4R)-
ENTEROLACTON
rac Enterolactone
(3R,4R)-3,4-Bis(3-hydroxybenzyl)dihydro-2(3H)-furanone
Compound 180/442
Description Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity[1]. Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis[2].
Related Catalog
In Vitro Enterolactone (25-75 μM; 48 hours) arrests the growth of MDA-MB-231 breast cancer cells in the ‘S’ phase[1] Enterolactone (25-75 μM; 15 hours) triggers apoptosis in MDA-MB-231 breast cancer cells via caspase-3 activation[1]. Enterolactone inhibits TGF-β-induced migration of MDA-MB-231 breast cancer cells. Enterolactone inhibits TGF-β-induced invasion of MDA-MB-231 breast cancer cells through ECM. Enterolactone inhibits the TGF-β-induced EMT program in MDA-MB-231 breast cancer cells. Enterolactone reduces the formation of actin stress fibers by inhibiting the expression of CD44 and MAPK-p38. Enterolactone inhibits the ERK/NF-κB/Snail signaling pathway to revert TGF-β-induced EMT in MDA-MB-231 cells[1]. Cell Viability Assay[1] Cell Line: MDA-MB-231 cells Concentration: 25, 50, 75 μM Incubation Time: 48 hours Result: There was a non-significant increase (~24%) in the S phase population following treatment with 25 μM EL, whereas there were significant increases (~34% and ~39%) following treatment with 50 and 75 μM EL, respectively.
References

[1]. Bigdeli B, et al. Enterolactone: A novel radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis. Toxicol Appl Pharmacol. 2016;313:180-194.

[2]. Mali AV, et al. Enterolactone modulates the ERK/NF-κB/Snail signaling pathway in triple-negative breast cancer cell line MDA-MB-231 to revert the TGF-β-induced epithelial-mesenchymal transition. Cancer Biol Med. 2018;15(2):137-156.

Density 1.3±0.1 g/cm3
Boiling Point 561.4±25.0 °C at 760 mmHg
Melting Point 141-143°C (lit.)
Molecular Formula C18H18O4
Molecular Weight 298.33
Flash Point 209.0±16.7 °C
Exact Mass 298.120514
PSA 66.76000
LogP 2.29
Vapour Pressure 0.0±1.6 mmHg at 25°C
Index of Refraction 1.635
Storage condition 2-8°C
Symbol GHS07
GHS07
Signal Word Warning
Hazard Statements H315-H319-H335
Precautionary Statements P261-P305 + P351 + P338
Hazard Codes Xi: Irritant;
Risk Phrases R36/37/38
Safety Phrases 26-36
RIDADR NONH for all modes of transport